As presented at the 2025 ASCO Annual Meeting: in a randomized controlled phase 3 trial evaluating subcutaneous administration of sasanlimab, an anti-PD-1 inhibitor, with Bacillus Calmette–Guérin induction and maintenance treatment, combination treatment significantly improved event-free survival versus standard-of-care therapy.
- Neal D. Shore
- Thomas B. Powles
- Gary D. Steinberg
